Does Vitamin Shoppe, Inc. Have a Healthier Future Than GNC Holdings Inc.?

Both Vitamin Shoppe and GNC recently reported earnings. And while both companies saw shares plummet after the news, Vitamin Shoppe’s results point to a quicker recovery than rival GNC's.

May 28, 2014 at 5:30PM

 Following the release of their latest quarterly earnings results, the market whipped shares of health and wellness retailers GNC Holdings (NYSE:GNC) and Vitamin Shoppe (NYSE:VSI) on May 6 and May 7. GNC's first quarter of fiscal 2014 had weak sales, which were attributed in part to a drop in demand for its diet products, which have lately fallen out of favor with consumers. However, Vitamin Shoppe's results seem to imply  more positive momentum for the remainder of the year. The company posted stronger sales during the first-quarter than its rival, especially in its direct-sales channel. While both companies faced a challenging quarter, Vitamin Shoppe seems to offer shareholders a better investment value going forward.

Market praises Vitamin Shoppe's management 
While top-line revenue showed strength, higher expenses were noted during the first quarter, mostly due to acquisition-related expenses and higher depreciation. Some of the first quarter's highlights are:

  • Total net sales for the quarter increased 10.3% to $307.8 million versus $279.1 million in the same quarter in 2013.
  • Total comp sales grew by 3.6% and the first quarter marked the 34th consecutive quarter of positive growth.
  • The e-commerce (direct-sales) channel posted a 17% increase in revenue
  • Net income was $20.5 million, down by $288,000
  • Diluted EPS dropped a penny to $0.67 from $0.68 in the same period in 2013
  • .

 Despite some short term issues, analysts at Barclays had high praise for Vitamin Shoppe's management and their focus on diversifying the company's business as well as the stable results achieved given the current environment. Two days after the first-quarter earnings release, they upgraded the stock to overweight from equal weight. The company is known for its broad product offerings much like its main rival GNC. Its offerings include vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. Vitamin Shoppe sells about 900 brands that include both independent brand names and its own proprietary brands.

As of March 29, there were 667 Vitamin Shoppe stores in operation, and direct sales to consumers are made through the company's and websites. During the quarter, the company opened nine stores, including one in Canada. Since the first quarter in 2013, Vitamin Shoppe has added 46 new stores and expects to open 60 additional locations during 2014.

How is the competition feeling in this challenging market?
In GNC's first quarter ended on March 31, the company reported weaker top-line results than its smaller rival Vitamin Shoppe. Consolidated revenue rose 1.9% to $677.3 million; the retail segment's revenue increased 3.1%, but the franchise and manufacturing segments declined by 1.4% and 2.2%, respectively. A decline of 0.7% in comp-store sales was blamed on bad winter weather during January and February.

While net income declined by 3.7% to $69.9 million, the company reported diluted EPS of $0.75, an increase of 2.7% compared to the same period last year. Management attributed the results to negative publicity about vitamins and supplements and weakness in third-party diet and pre-workout products. While these trends are expected to continue in the next few quarters, the company is responding by focusing on growing products categories such as fitness, enhanced marketing efforts, and offering value to customers through its member pricing program.

Another competitor in the vitamin and supplement space is CVS Caremark (NYSE:CVS), which has a broader selection of products for sale plus a retail pharmacy, its main revenue driver. The company's first quarter of fiscal 2014 had net revenue of $32.7 billion, up by 6.3% compared to the same period last year; the operating profit rose by 19.5% to about $2 billion. Comp-store sales increased during the quarter by 1.4% compared to 2013's first quarter; and while pharmacy same-store sales rose 3.8%, front store-same store sales dropped by 3.8%.

Both pharmacy and front store were negatively affected by the winter weather and a weaker-than-expected flu season, especially when compared to last year. While prescription volumes were negatively affected by 180 to 200 basis points, overall total same-store sales increased due to stronger prescription volumes and higher prices for brand-name drugs.

Foolish Takeaway
The Vitamin Shoppe is showing more optimism about its growth prospects for the remainder of 2014 than some of its competitors and is the better choice for investors. Shares trade at 15.8 times 2015 earnings and have a five-year expected PEG ratio of approximately 1.5.

Management is showing sound judgment by emphasizing and investing in an e-commerce strategy for its products, which are well suited for online shopping. Retail comp-store sales for 2014 are expected to grow by low- to mid-single digits; total comp-store sales, including e-commerce sales, are expected to grow in the mid-single digits.

GNC is more cautious about the rest of 2014, with same-store sales expected to stay flat or increase by low-single digits. It's been struggling lately, having missed market earnings estimates in the past two quarters. However, it is expanding its business abroad where it can encounter less competitive pressure. Managing costs and product pricing is critical for GNC, as well as Vitamin Shoppe, because a larger player, like CVS, with more competitive prices could lure some of its customers away.

Your credit card may soon be completely worthless
The plastic in your wallet is about to go the way of the typewriter, the VCR, and the 8-track tape player. When it does, a handful of investors could stand to get very rich. You can join them -- but you must act now. An eye-opening new presentation reveals the full story on why your credit card is about to be worthless -- and highlights one little-known company sitting at the epicenter of an earth-shaking movement that could hand early investors the kind of profits we haven't seen since the dot-com days. Click here to watch this stunning video.


Eileen Rojas has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information